298 related articles for article (PubMed ID: 33624556)
1. Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.
Taylor CM; Kasztan M; Sedaka R; Molina PA; Dunaway LS; Pollock JS; Pollock DM
Am J Physiol Regul Integr Comp Physiol; 2021 May; 320(5):R630-R640. PubMed ID: 33624556
[TBL] [Abstract][Full Text] [Related]
2. Combined hydroxyurea and ET
Taylor C; Kasztan M; Tao B; Pollock JS; Pollock DM
Acta Physiol (Oxf); 2019 Feb; 225(2):e13178. PubMed ID: 30144292
[TBL] [Abstract][Full Text] [Related]
3. Effects of hydroxyurea and L-arginine on the production of nitric oxide metabolites in cultures of normal and sickle erythrocytes.
Nahavandi M; Tavakkoli F; Millis RM; Wyche MQ; Habib MJ; Tavakoli N
Hematology; 2006 Aug; 11(4):291-4. PubMed ID: 17178670
[TBL] [Abstract][Full Text] [Related]
4. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
5. Impact of ET-1 and sex in glomerular hyperfiltration in humanized sickle cell mice.
Kasztan M; Pollock DM
Clin Sci (Lond); 2019 Jul; 133(13):1475-1486. PubMed ID: 31273050
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea does not reverse functional alterations of the nitric oxide-cGMP pathway associated with priapism phenotype in corpus cavernosum from sickle cell mouse.
Pereira DA; Pereira DA; da Silva Pereira P; Silveira THR; Calmasini FB; Reis LO; Costa FF; Silva FH
PLoS One; 2023; 18(10):e0292706. PubMed ID: 37812620
[TBL] [Abstract][Full Text] [Related]
7. Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.
Drawz P; Ayyappan S; Nouraie M; Saraf S; Gordeuk V; Hostetter T; Gladwin MT; Little J
Clin J Am Soc Nephrol; 2016 Feb; 11(2):207-15. PubMed ID: 26672090
[TBL] [Abstract][Full Text] [Related]
8. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress.
Kaul DK; Zhang X; Dasgupta T; Fabry ME
Am J Physiol Heart Circ Physiol; 2008 Jul; 295(1):H39-47. PubMed ID: 18456737
[TBL] [Abstract][Full Text] [Related]
9. Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy.
Morris CR
Hematol Oncol Clin North Am; 2014 Apr; 28(2):301-21. PubMed ID: 24589268
[TBL] [Abstract][Full Text] [Related]
10. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.
Hsu LL; Champion HC; Campbell-Lee SA; Bivalacqua TJ; Manci EA; Diwan BA; Schimel DM; Cochard AE; Wang X; Schechter AN; Noguchi CT; Gladwin MT
Blood; 2007 Apr; 109(7):3088-98. PubMed ID: 17158223
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
12. Acute hydroxyurea treatment reduces tubular damage following bilateral ischemia-reperfusion injury in a mouse model of sickle cell disease.
Park F; Soni H; Pressly JD; Adebiyi A
Biochem Biophys Res Commun; 2019 Jul; 515(1):72-76. PubMed ID: 31128920
[TBL] [Abstract][Full Text] [Related]
13. Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice.
Dasgupta T; Fabry ME; Kaul DK
Am J Physiol Regul Integr Comp Physiol; 2010 Feb; 298(2):R394-402. PubMed ID: 20007516
[TBL] [Abstract][Full Text] [Related]
14. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
[TBL] [Abstract][Full Text] [Related]
15. Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea.
Almeida CB; Souza LE; Leonardo FC; Costa FT; Werneck CC; Covas DT; Costa FF; Conran N
Blood; 2015 Aug; 126(6):711-20. PubMed ID: 26019278
[TBL] [Abstract][Full Text] [Related]
16. Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell Mice.
Steppan J; Tran HT; Bead VR; Oh YJ; Sikka G; Bivalacqua TJ; Burnett AL; Berkowitz DE; Santhanam L
Anesth Analg; 2016 Sep; 123(3):652-8. PubMed ID: 27537757
[TBL] [Abstract][Full Text] [Related]
17. Advances in sickle cell disease treatment: from drug discovery until the patient monitoring.
dos Santos JL; Lanaro C; Chin CM
Cardiovasc Hematol Agents Med Chem; 2011 Apr; 9(2):113-27. PubMed ID: 21401492
[TBL] [Abstract][Full Text] [Related]
18. Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin.
Kim-Shapiro DB; King SB; Bonifant CL; Kolibash CP; Ballas SK
Biochim Biophys Acta; 1998 Mar; 1380(1):64-74. PubMed ID: 9545536
[TBL] [Abstract][Full Text] [Related]
19. Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice.
Kasztan M; Fox BM; Lebensburger JD; Hyndman KA; Speed JS; Pollock JS; Pollock DM
Blood Adv; 2019 May; 3(9):1460-1475. PubMed ID: 31064747
[TBL] [Abstract][Full Text] [Related]
20. Influence of βS-Globin Haplotypes and Hydroxyurea on Arginase I Levels in Sickle Cell Disease.
Moreira JA; Machado RP; Laurentino MR; Lemes RP; Barbosa MC; Santos TE; Bandeira IC; Martins AM
Dis Markers; 2016; 2016():9172726. PubMed ID: 27274608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
